Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies-Reference-Cited by-同舟云学术

Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies

Published:2015-08-14 Issue:6249 Volume:349 Page:
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Williams Wilton B.¹,Liao Hua-Xin¹,Moody M. Anthony¹,Kepler Thomas B.²,Alam S. Munir¹,Gao Feng¹,Wiehe Kevin¹,Trama Ashley M.¹,Jones Kathryn¹,Zhang Ruijun¹,Song Hongshuo¹,Marshall Dawn J.¹,Whitesides John F.¹,Sawatzki Kaitlin²,Hua Axin²,Liu Pinghuang¹,Tay Matthew Z.¹,Seaton Kelly E.¹,Shen Xiaoying¹,Foulger Andrew¹,Lloyd Krissey E.¹,Parks Robert¹,Pollara Justin¹,Ferrari Guido¹,Yu Jae-Sung¹,Vandergrift Nathan¹,Montefiori David C.¹,Sobieszczyk Magdalena E.³,Hammer Scott³,Karuna Shelly⁴,Gilbert Peter⁵,Grove Doug⁵,Grunenberg Nicole⁴,McElrath M. Juliana⁴,Mascola John R.⁶,Koup Richard A.⁶,Corey Lawrence⁴,Nabel Gary J.⁶,Morgan Cecilia⁵,Churchyard Gavin⁷,Maenza Janine⁴,Keefer Michael⁸,Graham Barney S.⁶,Baden Lindsey R.⁹,Tomaras Georgia D.¹,Haynes Barton F.¹

Affiliation:

1. Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.

2. Department of Microbiology, Boston University School of Medicine, Boston, MA, USA.

3. Department of Medicine, Columbia University Medical Center, New York, NY, USA.

4. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

5. The Statistical Center for HIV/AIDS Research and Prevention (SCHARP), Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

6. Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

7. The Aurum Institute, Johannesburg, South Africa.

8. University of Rochester School of Medicine, Rochester, NY, USA.

9. Brigham and Women’s Hospital, Boston, MA, USA.

Abstract

Microbiota can mislead antibodies Unlike the response to many viral infections, most people do not produce antibodies capable of clearing HIV-1. Non-neutralizing antibodies that target HIV-1's envelope glycoprotein (Env) typically dominate the response, which is generated by B cells that cross-react with Env and the intestinal microbiota. Williams et al. analyzed samples from individuals who had received a vaccine containing the Env protein, including the gp41 subunit. Most of the antibodies were non-neutralizing and targeted gp41. The antibodies also reacted to intestinal microbiota, suggesting that preexisting immunity to microbial communities skews vaccineinduced immune responses toward an unproductive target. Science , this issue 10.1126/science.aab1253 .

Funder

NIH

NIAID

National Institute of Allergy and Infectious Diseases

Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery

NIH NIAID Duke University Center for AIDS Research

NIH NIAID HVTN Laboratory Center

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference72 articles.